Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Total Non-Current Liabilities (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Total Non-Current Liabilities for 4 consecutive years, with $10.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 34.78% to $10.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.5 million, a 34.78% decrease, with the full-year FY2025 number at $10.5 million, down 34.78% from a year prior.
  • Total Non-Current Liabilities was $10.5 million for Q4 2025 at Spruce Biosciences, up from $8.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $30.9 million in Q1 2023 to a low of $8.6 million in Q2 2025.
  • A 4-year average of $18.8 million and a median of $16.4 million in 2022 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 111.17% in 2023, then tumbled 51.83% in 2024.
  • Spruce Biosciences' Total Non-Current Liabilities stood at $17.0 million in 2022, then soared by 60.0% to $27.2 million in 2023, then plummeted by 40.79% to $16.1 million in 2024, then tumbled by 34.78% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Total Non-Current Liabilities are $10.5 million (Q4 2025), $8.6 million (Q2 2025), and $16.1 million (Q4 2024).